# PortfolioAI — Gate H H2 Closure Record

**Date:** 20 September 2026  
**Branch:** `r4n-pharma-subprofile-architecture`  
**PR:** #101 — OPEN / DRAFT / UNMERGED  
**Status:** COMPLETE / PASS

## H2 closure declaration

Owner declaration:

`H2 = COMPLETE / PASS`

Final validated TORNTPHARM H2 dimension inputs:

| Dimension | H2 value |
|---|---:|
| Quality | 92 |
| Growth | 78.25 |
| Capital Efficiency | 79 |
| Cash Flow | 93.6 |
| Balance Sheet / Credit | 65 |
| Business Durability | 75 |
| Valuation | 30 |
| Ownership / Governance | 70 |
| Momentum | 95 |
| Risk | 80 |

## Important methodology locks preserved

- Business Durability uses the frozen 35/25/20/20 parent weights.
- Brand / Therapy Leadership is owner-approved at STRONG / 75 using the independent AIOCD-derived cross-check plus current issuer AIOCD Pharmatrac evidence.
- Valuation uses `PHARMA_DOMESTIC_VALUATION_MA_TRANSITION_V1_OWNER_APPROVED` for the current M&A transition only.
- The base G6.17 40/40/20 Valuation contract is unchanged and resumes when comparable post-merger annual FCF becomes available.
- No hidden renormalization or double counting was introduced.

## Validation

Final closure validation:

- focused Business Durability test: PASS
- TypeScript typecheck: PASS
- all H2 evidence/methodology blockers: RESOLVED

## Boundary

H2 closure does **not** authorize or perform:

- H3 final company-score calculation;
- official score persistence;
- recommendation or position sizing;
- production Supabase mutation;
- PR #101 merge;
- deployment.

H3 must be started separately.

> **Gate H / H2 = COMPLETE / PASS**
